Corneal grafts from cancer patients more likely to cause infection

Article

Corneal grafts obtained from cancer patients may be associated with an increased risk of infection for the recipient, according to a study published in the February issue of Archives of Ophthalmology.

Corneal grafts obtained from cancer patients may be associated with an increased risk of infection for the recipient, according to a study published in the February issue of Archives of Ophthalmology.

Sohela Hassan and colleagues from the Baylor College of Medicine, Houston, USA, used data from a surveillance registry to determine whether the donor’s health status was associated with a risk of infection in the recipient. Donor information was collected for all cases of eye infection reported for transplants performed between 1994 and 2003.

During the study period, eye banks distributed 340,174 donor corneas in the US and 109,009 internationally. A total of 162 cases of endophthalmitis were reported. The odds of infected recipients having received a cornea from a hospitalized donor were three-times that of non-infected recipients. In addition, death of the donor from cancer was considerably more likely among recipients who developed infections. The cause is not yet clear, but donors may acquire harmful microorganisms in the hospital and transmit them to patients.

The results suggest that a donor’s health may affect their eye tissue, however, the authors do not recommend excluding broad categories of donors.

Recent Videos
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
John T. Thompson, MD, discusses his presentation at ASRS, Long-Term Results of Macular Hole Surgery With Long-Acting Gas Tamponade and Internal Limiting Membrane Peeling
ASRS 2024: Michael Singer, MD, shares 100-week results from the RESTORE trial
© 2024 MJH Life Sciences

All rights reserved.